Related Experiment Video
Updated: Jul 29, 2025
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Paclitaxel Protects against Isoproterenol-Induced Damage in Rat Myocardium: Its Heme-Oxygenase Mediated Role in
Danica Matusovits1, Zsolt Murlasits2, Krisztina Kupai3,4
1Department of Prosthodontics, Faculty of Dentistry, University of Szeged, 6703 Szeged, Hungary.
Abstract:
(1) Background: In cardiovascular applications, paclitaxel inhibits smooth muscle cell proliferation and migration and significantly reduces the occurrence of restenosis and target lesion revascularization. However, the cellular effects of paclitaxel in the myocardium are not well understood; (2) Methods: Wistar rats were divided into four groups: control (CTRL), isoproterenol (ISO) treated (1 mg/kg) and two groups treated with paclitaxel (PAC), which was administrated (10 mg/kg/day) for 5 days by gavage/per os alone or in combination (ISO + PAC) 3 weeks after ISO treatment. Ventricular tissue was harvested 24 h later for measurements of heme oxygenase (HO-1), reduced glutathione (GSH), oxidized glutathione (GSSG), superoxide dismutase (SOD), NF-κB, TNF-α and myeloperoxidase (MPO); (3) Results: HO-1 protein concentration, HO-1 activity, SOD protein concentration and total glutathione significantly decreased in response to ISO treatment. When PAC was administered in conjunction with ISO, HO-1, SOD concentration and total glutathione were not different from control levels. MPO activity, NF-κB concentration and TNF-α protein concentration were significantly increased in the ISO-only group, while the levels of these molecules were restored when PAC was co-administered; (4) Conclusions: Oral administration of PAC can maintain the expression of important antioxidants, anti-inflammatory molecules, HO-1, SOD and GSH, and suppress the production of TNF-α, MPO and NF-κB, which are involved in myocardial damage. The principal component of this cellular defense seems to be the expression of HO-1.
Insights
Paclitaxel (PAC) protects the heart by maintaining antioxidant levels and reducing inflammation. This study shows PAC administration can prevent myocardial damage caused by isoproterenol (ISO).
Area of Science:
- Cardiovascular Research
- Pharmacology
- Cellular Biology
Background:
- Paclitaxel (PAC) is known to prevent restenosis in cardiovascular applications.
- Its effects on the myocardium, the heart muscle, are not well understood.
- Isoproterenol (ISO) is used to induce cardiac stress in research models.
Purpose of the Study:
- To investigate the cellular effects of paclitaxel (PAC) on the myocardium.
- To determine if PAC can mitigate isoproterenol (ISO)-induced myocardial damage.
- To explore the role of antioxidants and inflammatory markers in PAC's protective effects.
Main Methods:
- Wistar rats were treated with isoproterenol (ISO) to induce cardiac stress.
- Paclitaxel (PAC) was administered orally, alone or with ISO.
- Levels of heme oxygenase (HO-1), glutathione (GSH/GSSG), superoxide dismutase (SOD), NF-κB, TNF-α, and myeloperoxidase (MPO) were measured in ventricular tissue.
Main Results:
- ISO treatment decreased HO-1, SOD, and glutathione levels, while increasing MPO, NF-κB, and TNF-α.
- Co-administration of PAC with ISO restored HO-1, SOD, and glutathione to control levels.
- PAC treatment suppressed the ISO-induced increases in MPO, NF-κB, and TNF-α.
Conclusions:
- Oral paclitaxel (PAC) administration preserves myocardial antioxidant defenses (HO-1, SOD, GSH).
- PAC suppresses key inflammatory markers (TNF-α, MPO, NF-κB) involved in cardiac damage.
- Heme oxygenase-1 (HO-1) appears central to paclitaxel's protective mechanism in the myocardium.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...